Can anyone explain why they are testing the efficacy of 5mg and 10mg dosage in XanaMIA in healthy adults, when the cognitive improvement we saw in healthy adults from XanaHES was on a 20mg dose? I'm not a scientist and won't pretend to understand, and I'm confident of course that our management know what they're doing... but can anyone explain why?
Ann: Trading Halt, page-25
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.003(13.0%) |
Mkt cap ! $80.14M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.7¢ | 2.5¢ | $457.1K | 17.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 3125379 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 173709 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |